UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstracts for References 1-4

of 'Overview of neurologic complications of non-platinum cancer chemotherapy'

1
 
 
DeAngelis LM, Posner JB. Side Effects of Chemotherapy. In: Neurologic Complications of Cancer, 2nd, Oxford University Press, New York 2009. p.447.
 
no abstract available
2
 
 
Dietrich J, Wen PY. Neurologic complications of chemotherapy. In: Cancer Neurology in Clinical Practice, 2nd, Schiff D, Kesari S, Wen PY (Eds), Humana Press, Totowa, New Jersey 2008. p.287.
 
no abstract available
3
TI
Neurological adverse effects caused by cytotoxic and targeted therapies.
AU
Schiff D, Wen PY, van den Bent MJ
SO
Nat Rev Clin Oncol. 2009;6(10):596. Epub 2009 Aug 25.
 
Historically, body tissues with a high rate of cell turnover, such as the bone marrow, have been most susceptible to chemotherapy-induced damage. The widespread use of hematopoietic colony-stimulating factors, as well as the development of new agents, has led to improved outcomes in many types of cancer. As a consequence, neurotoxicity has become increasingly important as a cause of dose-limiting chemotherapy toxicity. An understanding of the neurologic complications of these new agents is crucial in order to prevent irreversible neurologic injury. Moreover, chemotherapy complications that require discontinuation of a potentially effective drug need to be distinguished from other causes of neurotoxicity including the tumor itself, paraneoplasia, radiation and surgery, which may require a different therapeutic strategy. We review the prevalence, prevention, and management of important and unusual neurotoxicities related to chemotherapy and targeted agents approved by the FDA since January 1999. These agents include DNA-damaging agents such as oxaliplatin and temozolomide, microtubule poisons like ixabepilone, proteasome inhibitors (bortezomib), and signal transduction inhibitors such as imatinib, sunitinib and bevacizumab.
AD
Department of Neurology, University of Virginia in Charlottesville, VA 22908-0432, USA. davidschiff@virginia.edu
PMID
4
TI
Central and peripheral nervous system toxicity of common chemotherapeutic agents.
AU
Sioka C, Kyritsis AP
SO
Cancer Chemother Pharmacol. 2009;63(5):761.
 
Central and peripheral nervous system toxicity are frequent complications of most chemotherapy regimens, often leading to reduction of dosages or cessation of the responsible drugs. However, sometimes the afflicted toxicity may not be reversible, especially if it is not recognized early, further compromising the quality of life of the cancer patients. The most common chemotherapeutic agents that might cause CNS toxicity manifested as encephalopathy of various severities include methotrexate, vincristine, ifosfamide, cyclosporine, fludarabine, cytarabine, 5-fluorouracil, cisplatin and the interferons (alpha>beta). Involvement of the peripheral nervous system manifested as distal peripheral neuropathy results after therapy with cisplatin, vincristine, taxanes, suramin and thalidomide. Although several compounds have been proposed as neuroprotective agents, few have been shown to be active against the chemotherapy induced neurotoxicity.
AD
Neurosurgical Research Institute, University of Ioannina, 45110, Ioannina, Greece.
PMID